Tamoxifen is a hormone modulator that has been widely used as an anti-cancer agent. Typically, patients with estrogen receptor positive (ER-positive) breast tumors will receive Tamoxifen either as a first line treatment or as a second line treatment after surgery. Despite the benefit of using Tamoxifen as hormonal therapy in treating ER-positive breast cancers has been widely demonstrated in patients at early treatment stages, its effectiveness seems to be significantly reduced in patients after five years post-treatment. Interestingly, two thirds of the tumors that become resistant to Tamoxifen continue to express ER. Thus, it is necessary to develop novel strategies that can be applied to target both ER-positive Tamoxifen-resistant and estrogen-independent breast cancer cells

Investigations on the possibility of using Survivin inhibitors for the treatment of Tamoxifen-resistant or estrogen-independent breast cancers

2011 - NHRI Research Day “Elected paper” award

2010 - American Association for Cancer Research Scholar-in-training award finalist

2010 - The 15 th Taiwan Joint Cancer Conference “Outstanding research poster” award

2010 - NHRI Research Day “Excellent research poster” award

2009 - NHRI Research Day “Elected thesis” award

2009 - The University of Auckland International Doctoral Scholar